SLN Earnings & Financial Statements
Silence Therapeutics plc
$9.29
+$0.30(+3.40%)
31
Overall
40
Value
18
Tech
36
Quality
Market Cap
$558.14M
Volume
1.18M
52W Range
$4.19 - $17.58
Target Price
$35.80
SLN earnings and financial statements: Silence Therapeutics plc's income statement, balance sheet and cash flow statement, annual and quarterly.
SLN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2024 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | $142.0K | $33.83M | $1.14M | $15.70M | $25.38M |
| Cost of revenue | $54.0K | $9.24M | $2.77M | $2.80M | $10.32M |
| Operating income | -$28.41M | -$49.03M | -$22.54M | -$371.0K | -$49.60M |
| EBITDA | -$28.39M | -$44.54M | -$21.56M | $2.59M | -$47.66M |
| Net income | -$28.53M | -$35.24M | -$27.01M | $2.20M | -$43.27M |
| EPS (diluted) | $-0.20 | $-0.25 | $0.57 | $-0.02 | $-0.39 |
| Fiscal year | 2025 | 2024 | 2024 | 2024 | 2023 |
|---|---|---|---|---|---|
| Total assets | $185.30M | $161.64M | $169.38M | $194.38M | $93.82M |
| Total liabilities | $72.56M | $54.76M | $74.87M | $70.48M | $76.77M |
| Shareholders’ equity | -$112.74M | -$106.88M | $94.52M | $123.90M | $17.05M |
| Cash and equivalents | $64.89M | $96.79M | $61.95M | $113.06M | $54.03M |
| Long-term debt | $53.29M | $41.31M | $57.95M | $56.30M | $59.00M |
| Fiscal year | 2025 | 2024 | 2024 | 2024 | 2023 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.31M | -$54.13M | -$31.96M | -$9.14M | -$39.35M |
| Free cash flow | -$12.31M | -$54.30M | -$32.08M | -$9.14M | -$39.40M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLN | $9.29 | +3.4% | 1.18M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Silence Therapeutics plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW